Literature DB >> 18629938

SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans.

Huan Cao1, Ursula Lakner, Bernard de Bono, James A Traherne, John Trowsdale, Alexander D Barrow.   

Abstract

Sialic acid binding immunoglobulin-like lectins (Siglec) are important components of immune recognition. The organization of Siglec genes in different species is consistent with rapid selection imposed by pathogens. We studied SIGLEC11 genes in human, rodent, dog, cow and non-human primates. The lineages of SIGLEC11 genes in these species have undergone dynamic gene duplication and conversion, forming a potential inhibitory (SIGLEC11)/activating (SIGLEC16) receptor pair in chimpanzee and humans. A cDNA encoding human Siglec-16, currently classed as a pseudogene in the databases (SIGLECP16), is expressed in various cell lines and tissues. A polymorphism screen for the two alleles (wild type and four-base pair deletion, 4bpDelta) of SIGLEC16 found their frequencies to be 50% amongst the UK population. A search for donor sequences for SIGLEC16 revealed a subfamily of activating Siglec with charged transmembrane domains predicted to associate with ITAM-encoding adaptor proteins. In support of this, Siglec-16 was expressed at the cell surface in the presence of DAP12, but not the FcRgamma chain. Using antisera specific to the cytoplasmic tail of Siglec-16, we identified Siglec-16 expression in CD14(+) tissue macrophages and in normal human brain, cancerous oesophagus and lung. This is the first activating human Siglec receptor found to have functional and non-functional alleles within the population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629938     DOI: 10.1002/eji.200738078

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  39 in total

1.  Specific inactivation of two immunomodulatory SIGLEC genes during human evolution.

Authors:  Xiaoxia Wang; Nivedita Mitra; Ismael Secundino; Kalyan Banda; Pedro Cruz; Vered Padler-Karavani; Andrea Verhagen; Chris Reid; Martina Lari; Ermanno Rizzi; Carlotta Balsamo; Giorgio Corti; Gianluca De Bellis; Laura Longo; William Beggs; David Caramelli; Sarah A Tishkoff; Toshiyuki Hayakawa; Eric D Green; James C Mullikin; Victor Nizet; Jack Bui; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

Review 2.  Multifarious roles of sialic acids in immunity.

Authors:  Ajit Varki; Pascal Gagneux
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 5.691

Review 3.  Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

Authors:  Huan Cao; Paul R Crocker
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

4.  Natural ligands for CD33-related Siglecs?

Authors:  Ajit Varki
Journal:  Glycobiology       Date:  2009-05-09       Impact factor: 4.313

5.  Colloquium paper: uniquely human evolution of sialic acid genetics and biology.

Authors:  Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-05       Impact factor: 11.205

Review 6.  Evaluation of CD33 as a genetic risk factor for Alzheimer's disease.

Authors:  Steven Estus; Benjamin C Shaw; Nicholas Devanney; Yuriko Katsumata; Eileen E Press; David W Fardo
Journal:  Acta Neuropathol       Date:  2019-04-04       Impact factor: 17.088

7.  Evolution of siglec-11 and siglec-16 genes in hominins.

Authors:  Xiaoxia Wang; Nivedita Mitra; Pedro Cruz; Liwen Deng; Nissi Varki; Takashi Angata; Eric D Green; Jim Mullikin; Toshiyuki Hayakawa; Ajit Varki
Journal:  Mol Biol Evol       Date:  2012-03-01       Impact factor: 16.240

Review 8.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation.

Authors:  Bettina Linnartz; Yiner Wang; Harald Neumann
Journal:  Int J Alzheimers Dis       Date:  2010-06-22

Review 10.  Siglecs as targets for therapy in immune-cell-mediated disease.

Authors:  Mary K O'Reilly; James C Paulson
Journal:  Trends Pharmacol Sci       Date:  2009-04-07       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.